A newly published research demonstrated that oral administration of butyrate exerted antidiabetic effects in the T1D mouse model through promoting the serum C-peptide level, alleviating the islet lesions, and increasing numbers of islets and total insulin-positive islets (Yuan et al., 2022). Here, INS is linked to type 1 diabetes mellitus.